CCR4 and Hodgkins lymphoma: Anti-CCR4 mAb could be an excellent therapy option for individuals with CCR4+ neoplasms, as well as a novel strategy for treating cancers including HL, B-CLL, ovarian cancer, and EBV-associated disease, in which CCR4+ Tregs prevent the host immune response to the tumor or virus-infected cells (48).